JP2004504001A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004504001A5 JP2004504001A5 JP2000565168A JP2000565168A JP2004504001A5 JP 2004504001 A5 JP2004504001 A5 JP 2004504001A5 JP 2000565168 A JP2000565168 A JP 2000565168A JP 2000565168 A JP2000565168 A JP 2000565168A JP 2004504001 A5 JP2004504001 A5 JP 2004504001A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- cell
- target
- mrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004707 nucleic acids Proteins 0.000 claims 110
- 102000039446 nucleic acids Human genes 0.000 claims 110
- 150000007523 nucleic acids Chemical class 0.000 claims 110
- 230000027455 binding Effects 0.000 claims 104
- 238000009739 binding Methods 0.000 claims 104
- 108020004999 messenger RNA Proteins 0.000 claims 92
- 239000002773 nucleotide Substances 0.000 claims 63
- 125000003729 nucleotide group Chemical group 0.000 claims 63
- 108020005067 RNA Splice Sites Proteins 0.000 claims 48
- 125000006850 spacer group Chemical group 0.000 claims 27
- 239000013598 vector Substances 0.000 claims 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims 17
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 claims 16
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims 16
- 229920001184 polypeptide Polymers 0.000 claims 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims 15
- 108091092236 Chimeric RNA Proteins 0.000 claims 13
- 238000000034 method Methods 0.000 claims 13
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 11
- 230000000295 complement effect Effects 0.000 claims 8
- 239000013604 expression vector Substances 0.000 claims 6
- 230000003993 interaction Effects 0.000 claims 6
- 230000001404 mediated effect Effects 0.000 claims 6
- 201000003883 Cystic fibrosis Diseases 0.000 claims 5
- 230000015572 biosynthetic process Effects 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 230000004927 fusion Effects 0.000 claims 4
- 102000034356 gene-regulatory proteins Human genes 0.000 claims 2
- 108091006104 gene-regulatory proteins Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- 102000005720 Glutathione transferase Human genes 0.000 claims 1
- 108010070675 Glutathione transferase Proteins 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/133,717 US6083702A (en) | 1995-12-15 | 1998-08-13 | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| US09/158,863 US6280978B1 (en) | 1995-12-15 | 1998-09-23 | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| PCT/US1999/018371 WO2000009734A2 (en) | 1998-08-13 | 1999-08-12 | Methods and compositions for use in spliceosome mediated rna trans-splicing |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007177115A Division JP2007312780A (ja) | 1998-08-13 | 2007-07-05 | スプライソソーム媒介ｒｎａトランス−スプライシングにおける使用のための方法及び組成物 |
| JP2008182795A Division JP2009000120A (ja) | 1998-08-13 | 2008-07-14 | スプライソソーム媒介ｒｎａトランス−スプライシングにおける使用のための方法及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004504001A JP2004504001A (ja) | 2004-02-12 |
| JP2004504001A5 true JP2004504001A5 (enExample) | 2005-02-17 |
| JP4353390B2 JP4353390B2 (ja) | 2009-10-28 |
Family
ID=26831623
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000565168A Expired - Fee Related JP4353390B2 (ja) | 1998-08-13 | 1999-08-12 | スプライソソーム媒介ｒｎａトランス−スプライシングにおける使用のための方法及び組成物 |
| JP2007177115A Withdrawn JP2007312780A (ja) | 1998-08-13 | 2007-07-05 | スプライソソーム媒介ｒｎａトランス−スプライシングにおける使用のための方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007177115A Withdrawn JP2007312780A (ja) | 1998-08-13 | 2007-07-05 | スプライソソーム媒介ｒｎａトランス−スプライシングにおける使用のための方法及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6280978B1 (enExample) |
| EP (2) | EP1105513A2 (enExample) |
| JP (2) | JP4353390B2 (enExample) |
| AU (1) | AU773186B2 (enExample) |
| CA (1) | CA2339300C (enExample) |
| IL (1) | IL141409A0 (enExample) |
| WO (1) | WO2000009734A2 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020115207A1 (en) * | 1995-12-15 | 2002-08-22 | Mitchell Lloyd G. | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| US20020193580A1 (en) * | 1995-12-15 | 2002-12-19 | Mitchell Lloyd G. | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| US20030027250A1 (en) * | 1995-12-15 | 2003-02-06 | Mitchell Lloyd G. | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| US20060088938A1 (en) * | 1995-12-15 | 2006-04-27 | Mitchell Lloyd G | Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants |
| US20030077754A1 (en) * | 1995-12-15 | 2003-04-24 | Mitchell Lloyd G. | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| FR2790955B1 (fr) * | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
| GB2362383B (en) * | 2000-05-19 | 2003-12-31 | Devgen Nv | Gene expression system |
| WO2002008408A2 (en) * | 2000-07-21 | 2002-01-31 | Trustees Of Boston University | Modular vector systems |
| DE10057014B8 (de) * | 2000-11-17 | 2008-04-30 | Steven Dooley | Verfahren zur Herstellung von zielzellspezifischen Arzneimitteln |
| EP1358203A4 (en) * | 2001-01-08 | 2006-11-22 | Intronn Inc | METHOD AND COMPOSITION FOR CONNECTING IN SPLICEOSOME-MEDIATED RNA TRANS SPLICING |
| US20040126774A1 (en) * | 2001-01-08 | 2004-07-01 | Mitchell Lioyd G. | Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing |
| DE10139492B4 (de) * | 2001-08-13 | 2004-06-09 | Eul, Joachim, Dr. | Verfahren zur Reparatur einer mutierten RNA aus einer gendefekten DNA und zum gezielten Abtöten von Tumorzellen durch RNA-Transspleißen sowie Verfahren zum Nachweis von natürlich-transgespleißter zellulärer RNA |
| US20030153054A1 (en) * | 2002-02-12 | 2003-08-14 | Mitchell Lloyd G. | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| US20050137153A1 (en) * | 2002-02-20 | 2005-06-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA) |
| CA2477295A1 (en) * | 2002-02-25 | 2003-09-04 | Intronn, Inc. | Trans-splicing mediated imaging of gene expression |
| US7399753B2 (en) * | 2002-02-25 | 2008-07-15 | Virxsys Corporation | Trans-splicing mediated photodynamic therapy |
| US20040214263A1 (en) * | 2002-03-20 | 2004-10-28 | Mitchell Lloyd G. | Spliceosome mediated RNA trans-splicing |
| US20040018520A1 (en) * | 2002-04-22 | 2004-01-29 | James Thompson | Trans-splicing enzymatic nucleic acid mediated biopharmaceutical and protein |
| US20030204861A1 (en) * | 2002-04-30 | 2003-10-30 | Madaiah Puttaraju | Transgenic animal model for spliceosome-mediated RNA trans-splicing |
| JP2005536231A (ja) * | 2002-05-08 | 2005-12-02 | イントロン，インコーポレーテッド | アデノウイルスに細胞選択的複製をもたらすための、スプライセオソーム媒介型ｒｎａトランススプライシングの使用 |
| WO2003104412A2 (en) | 2002-06-05 | 2003-12-18 | Intronn, Inc. | Spliceosome mediated rna trans-splicing and correction of factor viii genetic defects using spliceosome mediated rna trans spling |
| EP1549755A4 (en) * | 2002-06-05 | 2006-09-20 | Intronn Inc | SPREAD OSOM-MEDIATED TRANS-RNA SPLEISSEN IN STEM CELLS |
| US20040018622A1 (en) * | 2002-07-17 | 2004-01-29 | Mitchell Lloyd G. | Spliceosome mediated RNA trans-splicing for correction of skin disorders |
| AU2003285009B2 (en) * | 2002-10-23 | 2010-10-07 | Virxsys Corporation | Screening methods for identification of efficient pre-trans-splicing molecules |
| WO2004087958A1 (en) * | 2003-03-31 | 2004-10-14 | Council Of Scientific And Industrial Research | Stn gene oligonucleotide primers for detecting salmonella species and detection prosses using the same |
| US8053232B2 (en) * | 2004-01-23 | 2011-11-08 | Virxsys Corporation | Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing |
| US7968334B2 (en) * | 2004-01-23 | 2011-06-28 | Virxsys Corporation | Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing |
| CA2553828A1 (en) * | 2004-01-23 | 2005-08-04 | Intronn, Inc. | Expression of apoa-1 and variants thereof using spliceosome mediated rna trans-splicing |
| US20060094110A1 (en) * | 2004-07-30 | 2006-05-04 | Mcgarrity Gerard J | Use of spliceosome mediated RNA trans-splicing for immunotherapy |
| US20060134658A1 (en) * | 2004-08-09 | 2006-06-22 | Garcia-Blanco Mariano A | Use of RNA trans-splicing for generation of interfering RNA molecules |
| DE102004047492B4 (de) * | 2004-09-23 | 2006-07-20 | Jost-Werke Gmbh & Co. Kg | Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem |
| US7871795B2 (en) * | 2004-10-08 | 2011-01-18 | Virxsys Corporation | Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins |
| JP5017118B2 (ja) * | 2004-10-08 | 2012-09-05 | バークシス コーポレーション | 組換えタンパク質をインビボ生産するための、非常に豊富な転写産物の標的化トランススプライシング |
| US7879321B2 (en) * | 2004-10-08 | 2011-02-01 | Virxsys Corporation | Use of RNA trans-splicing for antibody gene transfer and antibody polypeptide production |
| DE102006009000B3 (de) * | 2006-02-23 | 2007-09-06 | Tutech Innovation Gmbh | Rechengen |
| JP5081462B2 (ja) * | 2007-02-02 | 2012-11-28 | 富士フイルム株式会社 | トランススプライシング法による融合タンパク質作製方法 |
| EP2151248A1 (en) * | 2008-07-30 | 2010-02-10 | Johann Bauer | Improved pre-mRNA trans-splicing molecule (RTM) molecules and their uses |
| EP2326711A2 (en) * | 2008-08-20 | 2011-06-01 | VIRxSYS Corporation | Compositions and methods for generation of pluripotent stem cells |
| US8923125B2 (en) * | 2008-10-24 | 2014-12-30 | Qualcomm Incorporated | Wireless network resource adaptation |
| ES2578993T3 (es) | 2009-10-08 | 2016-08-03 | Association Institut De Myologie | Moléculas de ácido nucleico y métodos para intercambiar uno o más exones mediante corte y empalme en trans |
| WO2013016595A1 (en) | 2011-07-28 | 2013-01-31 | The Regents Of The University Of California | Exonic splicing enhancers and exonic splicing silencers |
| WO2014045283A1 (en) * | 2012-09-24 | 2014-03-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Restoration of the cftr function by splicing modulation |
| US9447411B2 (en) | 2013-01-14 | 2016-09-20 | Cellecta, Inc. | Methods and compositions for single cell expression profiling |
| WO2017087900A1 (en) | 2015-11-19 | 2017-05-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for correction of heritable ocular disease |
| CN109642241B (zh) * | 2016-04-01 | 2023-06-27 | 新加坡国立大学 | 反式剪接RNA（tsRNA） |
| KR20250150157A (ko) | 2018-04-17 | 2025-10-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 트랜스-스플라이싱 분자 |
| EP4013873A1 (en) | 2019-08-16 | 2022-06-22 | Massachusetts Institute Of Technology | Targeted trans-splicing using crispr/cas13 |
| EP4522758A2 (en) | 2022-05-13 | 2025-03-19 | Ascidian Therapeutics, Inc. | Abca4 trans-splicing molecules |
| EP4590825A1 (en) * | 2022-09-22 | 2025-07-30 | Rna Morph Ltd | Folding oligonucleotides |
| EP4594505A1 (en) | 2022-09-30 | 2025-08-06 | Centre National de la Recherche Scientifique | Therapy by trans-splicing of opa1 pre-messenger rnas for the treatment of diseases associated with opa1 gene mutations |
| CN120641122A (zh) | 2022-11-23 | 2025-09-12 | 安铂生物公司 | 基因修饰核酸内切酶 |
| WO2025128343A1 (en) | 2023-12-11 | 2025-06-19 | Just-Evotec Biologics, Inc. | Protein expression using trans-splicing and split selectable markers |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ241310A (en) * | 1991-01-17 | 1995-03-28 | Gen Hospital Corp | Trans-splicing ribozymes |
| NZ241311A (en) * | 1991-01-17 | 1995-03-28 | Gen Hospital Corp | Rna sequence having trans-splicing activity, plant strains |
| US5498531A (en) * | 1993-09-10 | 1996-03-12 | President And Fellows Of Harvard College | Intron-mediated recombinant techniques and reagents |
| US5667969A (en) * | 1993-11-12 | 1997-09-16 | University Research Corporation | Alteration of sequence of a deleterious target molecule by ribozyme catalyzed trans-splicing |
| EP0883344B2 (en) * | 1995-12-15 | 2010-06-09 | VIRxSYS Corporation | Therapeutic molecules generated by trans-splicing |
-
1998
- 1998-09-23 US US09/158,863 patent/US6280978B1/en not_active Expired - Lifetime
-
1999
- 1999-08-12 JP JP2000565168A patent/JP4353390B2/ja not_active Expired - Fee Related
- 1999-08-12 IL IL14140999A patent/IL141409A0/xx unknown
- 1999-08-12 AU AU56735/99A patent/AU773186B2/en not_active Ceased
- 1999-08-12 WO PCT/US1999/018371 patent/WO2000009734A2/en not_active Ceased
- 1999-08-12 EP EP99943690A patent/EP1105513A2/en not_active Withdrawn
- 1999-08-12 CA CA2339300A patent/CA2339300C/en not_active Expired - Fee Related
- 1999-08-12 EP EP04077408A patent/EP1489185A1/en not_active Withdrawn
-
2007
- 2007-07-05 JP JP2007177115A patent/JP2007312780A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004504001A5 (enExample) | ||
| Florence et al. | Ftz-F1 is a cofactor in Ftz activation of the Drosophila engrailed gene | |
| JP6614972B2 (ja) | 修飾ヘリカーゼ | |
| Shi et al. | Antisense imaging of gene expression in the brain in vivo | |
| JP6429773B2 (ja) | 酵素構築物 | |
| Scadden et al. | A ribonuclease specific for inosine‐containing RNA: a potential role in antiviral defence? | |
| KR20180089499A (ko) | 변형된 나노세공, 그를 포함하는 조성물, 및 그의 용도 | |
| CN105859829A (zh) | 纯化或检测靶蛋白的方法 | |
| CN111164097B (zh) | 一种Mnep单体变体及其应用 | |
| Sze et al. | In Vivo and In Vitro Effects of Integration Host Factor at the DmpR-Regulated ς54-Dependent Po Promoter | |
| CN112805393A (zh) | 一种解旋酶及其应用 | |
| Dauksaite et al. | Human Splicing Factor ASF/SF2 Encodes for a Repressor Domain Required for Its Inhibitory Activity on Pre-mRNA Splicing∗ | |
| Amundsen et al. | The RecB helicase-nuclease tether mediates Chi hotspot control of RecBCD enzyme | |
| JP2004525618A5 (enExample) | ||
| Manzan et al. | MlaA, a hexameric ATPase linked to the Mre11 complex in archaeal genomes | |
| Tsukamoto et al. | Differential expression in glioblastoma multiforme and cerebral hemangioblastoma of cytoplasmic proteins that bind two different domains within the 3'-untranslated region of the human glucose transporter 1 (GLUT1) messenger RNA. | |
| Sowden et al. | Apolipoprotein B RNA sequence 3′ of the mooring sequence and cellular sources of auxiliary factors determine the location and extent of promiscuous editing | |
| Fury et al. | Multiple protein: protein interactions between the snRNP common core proteins | |
| Mikheeva et al. | Use of an engineered ribozyme to produce a circular human exon | |
| JP2025526703A (ja) | 新規な細孔モノマー及び細孔 | |
| JP2025526704A (ja) | 新規な細孔モノマー及び細孔 | |
| JP2018029601A (ja) | アプタマーの製造方法 | |
| Paul et al. | Activation from a distance: roles of Lrp and integration host factor in transcriptional activation of gltBDF | |
| JP2000295993A (ja) | 二本鎖ｄｎａの特異的切断方法およびそのためのキット | |
| Ojha et al. | In vitro and in cellula site-directed RNA editing using the λNDD-BoxB system |